Trial · NCT04157335
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56 | Double Blind Benralizumab | -0.3 | Standard Deviation 1.6 | Score | |
| Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56 | Double Blind Placebo | -0.1 | Standard Deviation 1.3 | Score | |
| Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56. | Double Blind Benralizumab | -0.64 | Standard Deviation 0.98 | Score | |
| Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56. | Double Blind Placebo | -0.45 | Standard Deviation 0.90 | Score | |
| Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56. | Double Blind Benralizumab | -0.26 | Standard Deviation 0.78 | Score | |
| Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56. | Double Blind Placebo | -0.05 | Standard Deviation 0.56 | Score | |
| Sinus Opacification by CT Scan at Week 56. | Double Blind Benralizumab | -1.3 | Standard Deviation 3.4 | Score | |
| Sinus Opacification by CT Scan at Week 56. | Double Blind Placebo | -0.7 | Standard Deviation 3.5 | Score | |
| Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56. | Double Blind Benralizumab | -18.0 | Standard Error 29.6 | Score | |
| Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56. | Double Blind Placebo | -15.2 | Standard Error 26.6 | Score | |
| Time to First Nasal Polyp Surgery | Double Blind Benralizumab | 6.31 | Full Range 3.3 to 10.5 | Months | |
| Time to First Nasal Polyp Surgery | Double Blind Placebo | 7.79 | Full Range 4.4 to 12.4 | Months | |
| Time to First SCS Course for CRSwNP | Double Blind Benralizumab | 5.62 | Full Range 0.1 to 13.0 | Months | |
| Time to First SCS Course for CRSwNP | Double Blind Placebo | 6.37 | Full Range 0.1 to 11.4 | Months | |
| Time to First NP Surgery and/or SCS Use for CRSwNP | Double Blind Benralizumab | 5.70 | Full Range 0.1 to 13.0 | Months | |
| Time to First NP Surgery and/or SCS Use for CRSwNP | Double Blind Placebo | 6.37 | Full Range 0.1 to 12.4 | Months | |
| Change From Baseline in Bi-weekly Mean Nasal Polyps Symptom Diary Total Symptom Score at Week 56. | Double Blind Benralizumab | -3.19 | Standard Deviation 5.78 | Score | |
| Change From Baseline in Bi-weekly Mean Nasal Polyps Symptom Diary Total Symptom Score at Week 56. | Double Blind Placebo | -2.32 | Standard Deviation 5.83 | Score | |
| Percentage of Participants With Surgery and/or Use SCS for CRSwNP | Double Blind Benralizumab | 26 | Participants | ||
| Percentage of Participants With Surgery and/or Use SCS for CRSwNP | Double Blind Placebo | 30 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04157335/results